NCT01169298已完成1 期
A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Celgene
- 入组人数
- 13
- 试验地点
- 6
- 主要终点
- The safety of lenalidomide evaluated based on the severity of adverse events and their causality
研究概览
简要总结
To determine the maximum tolerated dose of lenalidomide in patients with adult T-cell leukemia-lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) who have previously received therapy for ATL and PTCL
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject must understand and voluntarily sign the written informed consent;
- •Aged 20 years or older;
- •Subject have a documented diagnosis of either:
- •Acute-, lymphoma-, or unfavorable chronic-type ATL or
- •Peripheral T-cell Lymphomaperipheral (PTCL)
- •Subject have received ≥1 prior anti-cancer therapy, have achieved stable disease (SD) or better on their immediately prior therapy and have relapsed or progressed at the time of obtaining signed informed consent;
- •Subject have an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 2 at enrollment;
排除标准
- •Natural Killer cell lymphoma (NK-cell lymphoma);
- •T-cell leukemia;
- •Cutaneous T-cell lymphoma (CTCL) including;
- •Mycosis fungoides
- •Sezary syndrome
- •CD30-positive lympho-proliferative disorders
- •Cutaneous gamma/delta T-cell lymphoma
- •Subject have a history of central nervous system (CNS) involvement or present with CNS symptoms, and are diagnosed with CNS lymphoma by cerebrospinal fluid (CSF) cytology examination, head CT scan or brain MRI during the screening;
- •Are pregnant or lactating;
- •Subject have uncontrolled inter-current illness including:
- •Uncontrolled diabetes mellitus
- •Chronic congestive heart failure (NYHA Class III or IV)
- •Unstable angina pectoris, angioplasty, stenting, or myocardial infarction (within 6 months before starting the study drug)
- •Clinically significant cardiac arrhythmia that is symptomatic or requires treatment, or asymptomatic sustained ventricular tachycardia
- •Other uncontrolled diseases
- •Exhibit grade 4 neurological disorders;
- •Subject have a history or complication of deep vein thrombosis or pulmonary embolism within 6 months before the start of study treatment;
- •Develop active tuberculous disease, herpes simplex, systemic mycosis, or other active infections requiring systemic administration of antibiotics, antiviral agents, or antifungal drugs;
- •Are tested positive for HBs antigen, anti-HCV antibody, or anti-HIV antibody;
- •Subjects have a history or complication for which the investigator or subinvestigator deems them inappropriate for this study, or have serious diseases or mental illness that is likely to be aggravated by participation in this study;
- •Subjects have a history of allogeneic stem cell transplantation;
- •Subjects have received autologous stem cell transplantation within 12 weeks (84 days) of the start of study treatment;
- •Have previously used lenalidomide;
- •Have a history of desquamating (bullous) rash while taking thalidomide;
- •Have received any investigational drugs (unapproved drugs in Japan) within 4 weeks (28 days) of the start of study medication;
- •Have received chemotherapeutic agents or immunomodulators for the treatment of ATL or PTCL within 4 weeks (28 days) of the start of study treatment;
- •Have received radiotherapy within 4 weeks (28 days) of the start of study treatment;
- •Have a history or complication of another malignant tumor than ATL or PTCL (excluding malignant tumors below), unless the patients have been free of the disease for 5 years or longer;
- •Cutaneous basal cell carcinoma or squamous cell carcinoma
- •Cervical carcinoma in situ
- •An incidental histological finding of prostate carcinoma (TNM stage T1a or T1b)
- •Have had any of the following abnormal measurements at screening performed within 1 week (7 days) prior to the enrollment;
- •Neutrophil count: < 1,200/µL (1.2 x 109/L)
- •Platelet count: < 75,000/µL (75 x 109/L)
- •Serum aspartate aminotransferase/ Serum glutamic oxaloacetic transaminase (AST/SGOT) or Alanine transaminase/Serum Glutamic Pyruvate Transaminase (ALT/SGPT): > 3 times the Upper Limit of Normal (ULN)
- •Bilirubin level: > 1.5 times of the ULN
- •Creatinine clearance: < 60 mL/min
研究组 & 干预措施
Lenalidomide
Experimental
Lenalidomide: 25mg daily on day1-21 of each 28days cycle (1st cohort), 25 mg daily of each 28 days (2nd cohort) or 35 mg daily of each 28 days (3rd cohort)
干预措施: Lenalidomide (Drug)
结局指标
主要结局
The safety of lenalidomide evaluated based on the severity of adverse events and their causality
时间窗: Up to 2.5 years
The safety of lenalidomide evaluated based on the severity of adverse events and their causality
次要结局
- PK-Apparent Volume of Distribution (Vz/F)(Day 8 of Cycle 1)
- Response(Up to 2.5 years)
- PK-Time to Maximum Plasma Concentration (Tmax)(Day 8 of Cycle 1)
- PK-Apparent Total Body Clearance (CL/F)(Day 8 of Cycle 1)
- PK-Terminal half-life (T1/2)(Day 8 of Cycle 1)
- Accumulation ratio (AUCτ)(Day 8 of Cycle 1)
- PK-Area under the Plasma concentration time curve (AUC)(Day 8 of Cycle 1)
- Accumulation ratio (Cmax)(Day 8 of Cycle 1)
- PK-Maximum Concentration in Plasma (Cmax)(Day 8 of cycle 1)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
2 期
A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphomaAdult T-Cell Leukemia-LymphomaNCT01724177Celgene26
已完成
2 期
Lenalidomide in HTLV-1 Adult T-Cell LeukemiaAdult T Cell Leukemia/LymphomaNCT01274533Columbia University4
终止
1 期
Lenalidomide In Patients With Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT00839059University of Ulm14
已完成
1 期
Study of Lenalidomide and Docetaxel in Subjects With Androgen Independent Prostate CancerProstate CancerNCT01378091Columbia University64
终止
1 期
Study of Theliatinib (HMPL-309) in Patients With Advanced Solid TumorCancerNCT02601274Hutchison Medipharma Limited33